drugset
drugset / Trial / NCT05839639

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT05839639 ↗

Phase 2 Completed 73 enrolled Huahui Health
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, controlled Phase IIa study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to evaluate the antiviral activity and safety in subjects with with HBeAg-negative Chronic Hepatitis B treated with nucleos(t)ide reverse transcriptase inhibitors.

Timeline

Start
2021-10-09
Primary completion
2022-12-05
Completion
2023-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Libevitug Monoclonal antibody 20 mg/kg Intravenous

Indications

chronic hepatitis B virus infection